Loading…
Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed
Purpose Cisplatin-pemetrexed is the first-line chemotherapy for advanced, metastatic non-squamous non-small cell lung cancer (NSCLC), but the risk of kidney toxicity limits the therapeutic schedule. We performed a retrospective study of patient survival at 1 year and glomerular filtration rate (GFR)...
Saved in:
Published in: | European journal of clinical pharmacology 2020-11, Vol.76 (11), p.1573-1580 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose
Cisplatin-pemetrexed is the first-line chemotherapy for advanced, metastatic non-squamous non-small cell lung cancer (NSCLC), but the risk of kidney toxicity limits the therapeutic schedule. We performed a retrospective study of patient survival at 1 year and glomerular filtration rate (GFR) outcomes in cisplatin-pemetrexed-treated NSCLC patients.
Methods
Patients (P) treated for NSCLC between 2008 and 2014 were divided into two groups according to GFR at diagnosis: G1 (GFR ≥ 90 mL/min/1.73 m
2
) and G2 (GFR between 60 and 89 mL/min/1.73 m
2
). GFR were compared in the two groups at 3 and 12 months. The following statistical methods were used: multivariate generalized estimating equation model for GFR outcome, Kaplan-Meier method for patient survival rate, and Cox model for analysing survival criteria.
Results
A total of 112 patients were included in the study (G1 = 87 P, G2 = 25 P). At 12 months, mean GFR significantly decreased by 28.4 mL/min/1.73 m
2
(− 22.3%,
p
= 0.001) in G1 and. 13.8 mL/min/1.73 m
2
(− 17.2%,
p
= 0.001) in G2. Median patient survival was 9.6 months (1.1–52.4) in G1 and 19.7 months (3.7–56.9) in G2. A better overall survival was significantly correlated with GFR between 60 and 89 mL/min/1.73 m
2
at diagnosis (
p
= 0.04), and higher cumulated doses of pemetrexed (
p
= 0.003) and cisplatin (
p
= 0.001).
Conclusion
The better survival rate in G2 and its correlation with pemetrexed and cisplatin treatments suggest that, until other therapeutic choices become available, a cautious increase in dosage could be investigated as a way to improve poor prognoses. |
---|---|
ISSN: | 0031-6970 1432-1041 |
DOI: | 10.1007/s00228-020-02935-8 |